Download PDF
GlaxoSmithKline has announced that its innovative heart drug darapladib has failed reduce heart attacks or other major cardiac events in patients suffering acute coronary syndrome.

This marks a further disappointment for the heart medicine that has previously failed to pass a late-stage trial for patients with well-treated heart disease. 

GSK’s President of Pharmaceuticals R&D Patrick Vallance expressed his disappointment with the result of the second phase III study that did not support a regulatory submission.

The company’s statement declared that the drug darapladib did not achieve the desired primary endpoint of a reduction of major coronary events versus placebo when added to standard of care.


13 May 2014

«« Cardiac Hypertrophy: Preventable via Protein


Heart Rhythm 2014: ZOLL Showcase to Include LifeVest Wearable Defibrillator »»


Heart, heart attack, heart disease, GSK, acute coronary syndrome, drug trails

Latest Articles

  • Pharmacist in the ICU

    Pharmacists play a crucial role in the ICU, where patients often require complex medication regimens, including multiple medications and intravenous therapies. The role of a critical care pharmacist is multifaceted and vital to ensuring optimal patient care in the critical care setting.   Cr

    READ MORE
  • Defining Medicines Optimisation in the Intensive Care Unit

      Complex polypharmacy and pathophysiology are common in the intensive care unit (ICU). Medicines optimisation is essential to deliver safe, effective, and individualised pharmacotherapy. This is ideally performed by a specialised ICU pharmacist.   Introduction Medicines ar

    READ MORE
  • Critical Care Pharmacists Save Lives

      The purpose of this review is to discuss the role of critical care pharmacists on the interprofessional healthcare team in the care of critically ill patients and explore current gaps in the provision of comprehensive medication management.   Introduction   “The patient’s

    READ MORE
Heart, heart attack, heart disease, GSK, acute coronary syndrome, drug trails GlaxoSmithKline has announced that its innovative heart drug darapladib has failed reduce heart attacks or other major cardiac events in patients suffering...